Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease

We previously demonstrated that pretreatment with Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) –mediated dopaminergic neurodegeneration. The use of GLP-1 or Exendin-4 for Parkinson’s disease (PD) patients is limited by the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shuchun, Yu, Seong-Jin, Li, Yazhou, Lecca, Daniela, Glotfelty, Elliot, Kim, Hee Kyung, Choi, Ho-Il, Hoffer, Barry J., Greig, Nigel H., Kim, Dong Seok, Wang, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048117/
https://www.ncbi.nlm.nih.gov/pubmed/30013201
http://dx.doi.org/10.1038/s41598-018-28449-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048117/
https://www.ncbi.nlm.nih.gov/pubmed/30013201
http://dx.doi.org/10.1038/s41598-018-28449-z

Ejemplares similares